Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering
Structure Therapeutics Inc. (NASDAQ: GPCR) is having a classic biotech moment on Tuesday, December 16, 2025: big catalyst, big financing, and now big volatility. Shares were down about 6% in Tuesday trading, recently around $60.73, after swinging between roughly $58.95 and $65.69 intraday. The pullback comes just days after the company reported positive topline Phase 2b results for its oral obesity candidate aleniglipron (GSBR-1290)—news that sparked a surge—followed immediately by an upsized equity raise that ultimately brought in about $747.5 million in gross proceeds. GlobeNewswire+1 Below is a detailed, up-to-date breakdown of the latest GPCR stock news (as of 16.12.2025),